Anakinra

IL-1 receptor antagonist

Response rate
~94%
Onset
Hours–days
Route
SC 100mg daily
Line
1st
IgM effect
No effect

Evidence summary

Blocks IL-1 receptor. Cornerstone treatment — fever and rash resolve within hours, CRP normalises within days. ~94% response across all published cases.

Molecular targets (1)

MoleculeRoleExpressionEvidence
IL-1βCentral pathogenic driverElevatedestablished

Sources (4)

G1Martinez-Taboada VM et al. (2005) First successful anakinra treatment · Arthritis RheumDOI ↗
G5Néel A et al. (2014) Multicenter anakinra study (29 patients, France) · Autoimmun RevDOI ↗
G6Szturz P et al. (2014) Czech multicenter anakinra study (6 patients) · Ann Rheum DisPubMed ↗
I9NHS England (2018) Anakinra as first-line treatment policy · NHS England